Off-Patent Industry Criticizes CMS’ Negotiated Price Drug List
The Biosimilars Forum And AAM Have Given Their Thoughts On The Negotiations
Off-patent industry groups in the US have raised questions about why Stelara is included on the list and if CMS’ projection can match up with estimated savings that could be generated traditionally by generics and biosimilars.
